State Demands Faster Price Caps on Life‑Saving Medicines
Karnataka’s health ministry has pressed the centre to accelerate the implementation of price‑control measures for critical drugs. The demand follows a Supreme Court observation that the gap between wholesale purchase price and the final price paid by patients is growing unsustainably.
In a circular dated October 1, the state instructed hospitals to list both the landing cost and the MRP of each medicine on patient bills, aiming for greater transparency. Though the circular currently carries a consultative status, officials plan to make it mandatory from November 1, 2026.
The state identified 253 pharmaceutical products with striking price disparities during on‑ground audits. Among these are high‑cost oncology medicines, as well as drugs for cardiovascular and renal diseases. Karnataka seeks to bring these under the Drug Price Control Order, limiting commercial margins to 30 per cent for non‑scheduled cancer drugs, as provisionally approved by the NPPP in its 283rd meeting.
A multi‑ministerial expert committee has been recommended to assess which medicines should fall within price‑control limits, with a report expected by October 14. Officials estimate that the proposed steps could shave 20‑70 per cent off MRPs of several cancer drugs, potentially saving around ₹2,500 crore nationwide.